middle.news
Nyrada’s NYR-BI03 Cuts Heart Attack Damage and Arrhythmias in Preclinical Tests
3:00am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Nyrada’s NYR-BI03 Cuts Heart Attack Damage and Arrhythmias in Preclinical Tests
3:00am on Monday 2nd of June, 2025 AEST
Key Points
NYR-BI03 reduces heart muscle injury size by 42% at higher doses
Significant drop in Troponin I and ALT biomarkers linked to cardiac and liver injury
Marked decrease in ventricular arrhythmias, including complete suppression of ventricular fibrillation
Short-duration intravenous infusion effective post-heart attack in preclinical rodent model
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nyrada (ASX:NYR)
OPEN ARTICLE